Lundbeck A/S (Lundbeck) announced positive results, meeting its primary endpoint, in the multiple IV dosing part of PROCEED, an adaptive phase IIb dose-finding and route of administration trial of bocunebart (Lu AG09222).
) The IIBBoard of Governors summarized the Bank's results in 2025 ... The IIB's management reported on the results of implementing measures aimed at further stabilizing the Bank's operations and strengthening its operational framework.
As a result, it was found that SN 2022ngb is a faint and slow-evolving Type IIb supernova with a low-mass envelope ... Potential Type IIb supernova ... a faint, slow-evolving Type IIb Supernova with a low-mass envelope, arXiv (2025).